This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Michel, G. Articles by Baruchel, A. Search for Related Content PubMed PubMed Citation Articles by Michel, G. Articles by Baruchel, A.

Use of Recombinant Human Granulocyte Colony-Stimulating Factor to Increase Chemotherapy Dose-Intensity: A Randomized Trial in Very High-Risk Childhood Acute Lymphoblastic Leukemia

From the University Hospital Centers at Marseille, Paris-Trousseau, Paris-St Louis, Rennes, Nancy, Tours, Clermont-Ferrand, Bordeaux, Brest, Bayonne, Amiens, and Rouen, France.

Address reprint requests to Gérard Michel, MD, Pédiatrie et Hématologie Pédiatrique, Hôpital d’Enfants La Timone, 264 Rue St Pierre, 13385, Marseille Cedex 05, France; email gmichel{at}ap-hm.fr

PURPOSE: To determine whether the use of a recombinant human granulocyte colony-stimulating factor ([G-CSF] lenogastrim) can increase the chemotherapy dose-intensity (CDI) delivered during consolidation chemotherapy of childhood acute lymphoblastic leukemia (ALL).

PATIENTS AND METHODS: Sixty-seven children with very high-risk ALL were randomized (slow early response to therapy, 55 patients; translocation t(9;22) or t(4;11), 12 patients). Consolidation consisted of six courses of chemotherapy; the first, third, and fifth courses were a combination of high-dose cytarabine, etoposide, and dexamethasone (R3), whereas the second, fourth, and sixth courses included vincristine, prednisone, cyclophosphamide, doxorubicin, and methotrexate (COPADM). G-CSF was given after each course, and the next scheduled course was started as soon as neutrophil count was > 1 x 10⁹/L and platelet count was > 100 x 10⁹/L. CDI was calculated using the interval from day 1 of the first course to hematologic recovery after the fifth course (100% CDI = 105-day interval).

RESULTS: CDI was significantly increased in the G-CSF group compared with the non–G-CSF group (mean ± 95% confidence interval, 105 ± 5% v 91 ± 4%; P < .001). This higher intensity was a result of shorter post-R3 intervals in the G-CSF group, whereas the post-COPADM intervals were not statistically reduced. After the R3 courses, the number of days with fever and intravenous antibiotics and duration of hospitalization were significantly decreased by G-CSF, whereas reductions observed after COPADM were not statistically significant. Duration of granulocytopenia was reduced in the G-CSF group, but thrombocytopenia was prolonged, and the number of platelet transfusions was increased. Finally, the 3-year probability of event-free survival was not different between the two groups.

CONCLUSION: G-CSF can increase CDI in high-risk childhood ALL. Its effects depend on the chemotherapy regimen given before G-CSF administration. In our study, a higher CDI did not improve disease control.

This article has been cited by other articles:

				P. Ballerini, J. Landman-Parker, J. M. Cayuela, V. Asnafi, M. Labopin, V. Gandemer, Y. Perel, G. Michel, T. Leblanc, C. Schmitt, et al. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome Haematologica, November 1, 2008; 93(11): 1658 - 1665. [Abstract] [Full Text] [PDF]

				L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection Ann Intern Med, September 18, 2007; 147(6): 400 - 411. [Abstract] [Full Text] [PDF]

				T. Lehrnbecher, M. Zimmermann, D. Reinhardt, M. Dworzak, J. Stary, and U. Creutzig Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia Blood, February 1, 2007; 109(3): 936 - 943. [Abstract] [Full Text] [PDF]

				L. Sung, J. Beyene, J. Hayden, P. C. Nathan, B. Lange, and G. A. Tomlinson A Bayesian Meta-analysis of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor in Children with Cancer Am. J. Epidemiol., May 1, 2006; 163(9): 811 - 817. [Abstract] [Full Text] [PDF]

				L. Sung, P. C. Nathan, B. Lange, J. Beyene, and G. R. Buchanan Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile Neutropenia After Chemotherapy in Children With Cancer: A Meta-Analysis of Randomized Controlled Trials J. Clin. Oncol., August 15, 2004; 22(16): 3350 - 3356. [Abstract] [Full Text] [PDF]

				J. A. Heath, P. G. Steinherz, A. Altman, H. Sather, S. Jhanwar, S. Halpern, R. Pieters, N. Shah, L. Steinherz, R. Tannous, et al. Human Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia: A Children's Cancer Group Study J. Clin. Oncol., April 15, 2003; 21(8): 1612 - 1617. [Abstract] [Full Text] [PDF]

				N. Boissel, M.-F. Auclerc, V. Lheritier, Y. Perel, X. Thomas, T. Leblanc, P. Rousselot, J.-M. Cayuela, J. Gabert, N. Fegueux, et al. Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials J. Clin. Oncol., March 1, 2003; 21(5): 774 - 780. [Abstract] [Full Text] [PDF]

				P. Ballerini, A. Blaise, M. Busson-Le Coniat, X. Y. Su, J. Zucman-Rossi, M. Adam, J. van den Akker, C. Perot, B. Pellegrino, J. Landman-Parker, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis Blood, July 18, 2002; 100(3): 991 - 997. [Abstract] [Full Text] [PDF]

				C. Patte, A. Laplanche, A. I. Bertozzi, A. Baruchel, D. Frappaz, C. Schmitt, F. Mechinaud, B. Nelken, P. Boutard, and J. Michon Granulocyte Colony-Stimulating Factor in Induction Treatment of Children With Non-Hodgkin's Lymphoma: A Randomized Study of the French Society of Pediatric Oncology J. Clin. Oncol., January 15, 2002; 20(2): 441 - 448. [Abstract] [Full Text] [PDF]